A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 4, 2015, Pages 371-376

  Matavelli, Luis C ^a,b   Zatz, Roberto ^a   Siragy, Helmy M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Angiotensin II type 2 receptor; C21; Diabetes; Inflammation; Kidney; Oxidative stress

Indexed keywords

8-EPI-PROSTAGLANDIN F2ALPHA; ANGIOTENSIN 2 RECEPTOR; CYCLIC GMP; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; PROSTAGLANDIN F2 ALPHA; TUMOR NECROSIS FACTOR;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; INFLAMMATION; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; DINOPROST; INFLAMMATION; INTERLEUKIN-6; KIDNEY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939998893     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000207     Document Type: Article

References (37)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
2. Awad AS, Webb RL, Carey RM, et al. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. Am J Hypertens. 2005;18:544-548.
3. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010;6: 319-330.
4. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
5. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989;36: 526-536.
6. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
7. Teles F, Machado FG, Ventura BH, et al. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int. 2009;75:72-79.
8. Parving HH, Lehnert H, Bröchner-Mortensen J, et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-860.
9. Brenner BM, Cooper ME, de Zeeuw D, et al RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
10. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433-442.
11. Siragy HM, Awad A, Abadir P, et al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology. 2003;144:2229-2233.
12. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012; 30:49-59.
13. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin (PG) E2 production in conscious rats. J Clin Invest. 1996;97:1979-1982.
14. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997; 100:264-269.
15. Siragy HM, Jaffa AA, Margolius HS, et al. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol. 1996;271:R1090-R1095.
16. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol Ren Physiol. 1999;276:F39-F45.
17. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
18. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118: 2523-2532.
19. Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
20. Matavelli LC, Huang J, Siragy HM. Angiotensin II type 2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308-313.
21. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology. 2009;150:5557-5565.
22. Verdonk K, Durik M, Abd-Alla N, et al. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 2012;60:722-729.
23. Han Y, Runge MS, Braiser AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ Res. 1999;84: 695-703.
24. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol. 2007;18:2439-2446.
25. Awad AS, Webb RL, Carey RM, et al. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens. 2004;22:1571-1577.
26. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93:817-824.
27. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol. 2010;37:277-282.
28. Matavelli LC, Huang J, Siragy HM. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. J Cardiovasc Pharmacol. 2012;59:281-287.
29. Matavelli LC, Huang J, Siragy HM. Reduction of aldosterone production improves renal fibrosis in diabetic rats. J Cardiovasc Pharmacol. 2013; 61:17-22.
30. Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-2301.
31. Savoia C, Touyz RM, Volpe M, et al. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-346.
32. Hilliard LM, Jones ES, Steckelings UM, et al. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension. 2012;59:409-414.
33. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappa B. Hypertension. 2010;55: 924-931.
34. Hakam AC, Hussain T. Renal AT2 receptors are upregulated and mediate the candesartan induced natriuresis/diuresis in obese zucker rats. Hypertension. 2005;45:270-275.
35. Hakam AC, Siddiqui AH, Hussain T. Renal angiotensin II AT2 receptors promote natriuresis in STZ-induced diabetes rats. Am J Physiol Renal Physiol. 2006;290:F503-F508.
36. Wehbi GJ, Zimpelmann J, Carey RM, et al. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol. 2001;280:F254-F265.
37. Bonnet F, Candido R, Carey RM, et al. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J Hypertens. 2002;20:1615-1624.